United Therapeutics (UTHR) EBT (2009 - 2026)

United Therapeutics (UTHR) has 18 years of EBT data on file, last reported at $318.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 24.84% year-over-year to $318.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 billion (up 2.86% YoY), and the FY2025 full-year result was $1.7 billion, up 11.36% from the prior year.
• EBT fell to $318.3 million in Q1 2026, from $444.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $444.0 million in Q4 2025 to a low of $150.6 million in Q2 2022.
• A 5-year average of $340.9 million and a median of $351.8 million in 2023 frame the typical range for EBT.
• Peak annual rise in EBT reached 849.85% in 2022, while the deepest fall reached 30.44% in 2022.
• Tracing UTHR's EBT over 5 years: stood at $178.8 million in 2022, then soared by 65.21% to $295.4 million in 2023, then soared by 34.22% to $396.5 million in 2024, then grew by 11.98% to $444.0 million in 2025, then declined by 28.31% to $318.3 million in 2026.
• Business Quant data shows UTHR's EBT at $318.3 million in Q1 2026, $444.0 million in Q4 2025, and $438.0 million in Q3 2025.